8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 22, 2026·SEC
Material company update
May 15, 2026·SEC
Moleculin Biotech, Inc.(MBRX)Earnings, Financials & Key Ratios
MBRX•NASDAQ
Price updated Jun 19, 2026
AboutMoleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.Show more
- Revenue$0
- EBITDA-$25M+5.7%
- Net Income-$34M-54.2%
- EPS (Diluted)-28.42+82.0%
- ROE-319.85%-135.5%
MBRX Key Insights
Moleculin Biotech, Inc. (MBRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 95 (top 5%)
✗Weaknesses
- ✗Profits declining 14.1% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MBRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MBRX Price & Volume
Moleculin Biotech, Inc. (MBRX) stock price & volume — 10-year historical chart
Loading chart...
MBRX Growth Metrics
Moleculin Biotech, Inc. (MBRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM98.49%
Return on Capital
10 Years-84.59%
5 Years-94.14%
3 Years-127.21%
Last Year-187.07%
MBRX Recent Earnings
Moleculin Biotech, Inc. (MBRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$2.48-46.7%
$1.69
Rev
—
—
Q2 2026
Mar 20, 2026Metric
Actual
Est
EPS
$2.61+133.6%
$7.77
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$3.25+35.0%
$5.00
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$12.25-25.6%
$9.75
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $2.48vs $1.69-46.7% | — |
| Q2 2026 | Mar 20, 2026 | $2.61vs $7.77+133.6% | — |
| Q4 2025 | Nov 13, 2025 | $3.25vs $5.00+35.0% | — |
| Q3 2025 | Aug 12, 2025 | $12.25vs $9.75-25.6% | — |
Based on last 12 quarters of dataView full earnings history →
MBRX Peer Comparison
Moleculin Biotech, Inc. (MBRX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 |
Compare MBRX vs Peers
Moleculin Biotech, Inc. (MBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MBRX Income Statement
Moleculin Biotech, Inc. (MBRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 18K | 68K | 185K | 0 | 0 | 0 | 0 | 0 | 90K | 37K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -18K▲ 0% | -68K▼ 277.8% | -185K▼ 172.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -90K▲ 0% | -37K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -192.11% | -277.78% | -172.06% | 100% | - | - | - | - | - | - |
Operating Expenses | 8.65M | 15.03M | 17.34M | 19.74M | 22.97M | 30.64M | 29.63M | 26.64M | 25.1M | 27M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 4.09M | 5.3M | 6.33M | 6.79M | 8.39M | 11.54M | 10.02M | 8.79M | 9.12M | 9.13M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 4.54M | 9.73M | 11.01M | 12.76M | 14.42M | 18.97M | 19.49M | 17.73M | 15.89M | 17.83M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 18K | -40K | 0 | 200K | 164K | 130K | 127K | 126K | 90K | 38K |
Operating Income | -8.65M▲ 0% | -15.03M▼ 73.6% | -17.52M▼ 16.6% | -19.74M▼ 12.7% | -22.97M▼ 16.3% | -30.64M▼ 33.4% | -29.63M▲ 3.3% | -26.64M▲ 10.1% | -25.1M▲ 5.8% | -27.03M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -122.83% | -73.64% | -16.63% | -12.66% | -16.34% | -33.4% | 3.29% | 10.09% | 5.77% | - |
EBITDA | -8.63M | -14.96M | -17.34M | -19.54M | -22.8M | -30.51M | -29.5M | -26.52M | -25.01M | -26.96M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -122.72% | -73.21% | -15.93% | -12.71% | -16.69% | -33.79% | 3.3% | 10.13% | 5.66% | -4.59% |
D&A (Non-Cash Add-back) | 18K | 68K | 185K | 200K | 164K | 130K | 127K | 126K | 90K | 68K |
EBIT | -8.49M | -15.06M | -13.43M | -19.74M | -22.97M | -30.64M | -29.63M | -26.64M | -25.1M | -28.95M |
Net Interest Income | 0 | 0 | 13K | 13K | 306K | 240K | 1.37M | 550K | 105K | 108K |
Interest Income | 0 | 0 | 13K | 13K | 306K | 240K | 1.37M | 550K | 105K | 108K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -1.15M | 3.15M | 4.09M | 2.39M | 7.07M | 1.61M | -138K | 4.88M | -8.46M | -3.3M |
Pretax Income | -9.8M▲ 0% | -11.88M▼ 21.1% | -13.43M▼ 13.1% | -17.36M▼ 29.2% | -15.89M▲ 8.4% | -29.02M▼ 82.6% | -29.77M▼ 2.6% | -21.76M▲ 26.9% | -33.56M▼ 54.2% | -30.33M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | -229K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 1.7% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -9.8M▲ 0% | -11.88M▼ 21.1% | -13.21M▼ 11.2% | -17.36M▼ 31.4% | -15.89M▲ 8.4% | -29.02M▼ 82.6% | -29.77M▼ 2.6% | -21.76M▲ 26.9% | -33.56M▼ 54.2% | -30.33M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -149.72% | -21.12% | -11.19% | -31.43% | 8.42% | -82.62% | -2.56% | 26.89% | -54.21% | -30.58% |
Net Income (Continuing) | -9.8M | -11.88M | -13.21M | -17.36M | -15.89M | -29.02M | -29.77M | -21.76M | -33.56M | -30.33M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1188.00▲ 0% | -1031.50▲ 13.2% | -729.50▲ 29.3% | -661.00▲ 9.4% | -221.75▲ 66.5% | -380.50▼ 71.6% | -376.75▲ 1.0% | -158.00▲ 58.1% | -28.42▲ 82.0% | -0.74▲ 0% |
EPS Growth % | -32.15% | 13.17% | 29.28% | 9.39% | 66.45% | -71.59% | 0.99% | 58.06% | 82.01% | 98.49% |
EPS (Basic) | -1188.00 | -1031.50 | -729.50 | -661.00 | -221.75 | -380.50 | -376.75 | -158.00 | -28.42 | - |
Diluted Shares Outstanding | 8.25K | 11.51K | 18.1K | 26.25K | 71.67K | 76.28K | 79.02K | 137.72K | 11.85M | 41.24M |
Basic Shares Outstanding | 8.25K | 11.51K | 18.1K | 26.25K | 71.67K | 76.28K | 79.02K | 137.72K | 11.85M | 41.24M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MBRX Balance Sheet
Moleculin Biotech, Inc. (MBRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.3M | 7.97M | 13.48M | 17.2M | 72.5M | 45.6M | 26.27M | 5.19M | 9.69M | 10.96M |
Cash & Short-Term Investments | 7.71M | 7.13M | 10.73M | 15.17M | 70.9M | 43.15M | 23.55M | 4.28M | 8.88M | 10.32M |
Cash Only | 7.71M | 7.13M | 10.73M | 15.17M | 70.9M | 43.15M | 23.55M | 4.28M | 8.88M | 10.32M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 56K | 11K | 1K | 45K | 0 | 0 | 0 | 7K | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 784K | 2.39M | 1.45M | 486K | 823K | 644K | 351K | 801K | 644K |
Total Non-Current Assets | 11.18M | 11.61M | 11.75M | 11.96M | 11.59M | 11.83M | 11.94M | 11.73M | 12.44M | 12.4M |
Property, Plant & Equipment | 33K | 463K | 603K | 685K | 445K | 678K | 796K | 583K | 314K | 284K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M |
Long-Term Investments | 0 | 0 | 0 | 129K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 978K | 970K |
Total Assets | 19.48M▲ 0% | 19.59M▲ 0.5% | 25.23M▲ 28.8% | 29.16M▲ 15.6% | 84.09M▲ 188.4% | 57.42M▼ 31.7% | 38.22M▼ 33.4% | 16.93M▼ 55.7% | 22.13M▲ 30.7% | 23.36M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 18.85% | 0.52% | 28.85% | 15.55% | 188.37% | -31.71% | -33.45% | -55.71% | 30.73% | 13.34% |
Total Current Liabilities | 2.21M | 3.88M | 3.57M | 2.92M | 3.62M | 4.82M | 6.82M | 5.36M | 6.85M | 7.96M |
Accounts Payable | 810K | 1.25M | 2.15M | 1.13M | 1.36M | 2.1M | 2.5M | 2.03M | 3.51M | 4.57M |
Days Payables Outstanding | 16.43K | 6.69K | 4.25K | - | - | - | - | - | 14.23K | 34.33K |
Short-Term Debt | 0 | 0 | 103K | 118K | 96K | 0 | 0 | 0 | 137K | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.16M | 2.29M | 878K | 1.25M | 1.56M | 0 | 0 | 0 | 3.21M | 3.39M |
Current Ratio | 3.75x | 2.06x | 3.78x | 5.89x | 20.02x | 9.46x | 3.86x | 0.97x | 1.41x | 1.38x |
Quick Ratio | 3.75x | 2.06x | 3.78x | 5.89x | 20.02x | 9.46x | 3.86x | 0.97x | 1.41x | 1.38x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 150K | 1.44M | 6.09M | 8.35M | 1.48M | 412K | 5.33M | 5.59M | 266K | 218K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 185K |
Capital Lease Obligations | 0 | 0 | 276K | 159K | 63K | 335K | 474K | 358K | 222K | 772K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 150K | 1.44M | 5.82M | 8.19M | 1.41M | 77K | 4.86M | 5.23M | 44K | 33K |
Total Liabilities | 2.37M | 5.31M | 9.66M | 11.27M | 5.1M | 5.23M | 12.14M | 10.95M | 7.12M | 8.18M |
Total Debt | 0 | 0 | 379K | 277K | 159K | 451K | 574K | 478K | 359K | 185K |
Net Debt | -7.71M | -7.13M | -10.36M | -14.9M | -70.74M | -42.69M | -22.98M | -3.8M | -8.52M | -10.13M |
Debt / Equity | - | - | 0.02x | 0.02x | 0.00x | 0.01x | 0.02x | 0.08x | 0.02x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.38x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 17.12M▲ 0% | 14.27M▼ 16.6% | 15.57M▲ 9.1% | 17.89M▲ 14.9% | 78.99M▲ 341.6% | 52.19M▼ 33.9% | 26.07M▼ 50.0% | 5.98M▼ 77.1% | 15.01M▲ 151.0% | 15.18M▲ 0% |
Equity Growth % | 14.42% | -16.63% | 9.1% | 14.89% | 341.57% | -33.93% | -50.04% | -77.07% | 150.98% | 35600.57% |
Book Value per Share | 2074.15 | 1239.64 | 860.37 | 681.36 | 1102.19 | 684.22 | 329.94 | 43.41 | 1.27 | 0.37 |
Total Shareholders' Equity | 17.12M | 14.27M | 15.57M | 17.89M | 78.99M | 52.19M | 26.07M | 5.98M | 15.01M | 15.18M |
Common Stock | 21K | 29K | 46K | 69K | 29K | 29K | 33K | 3K | 3K | 5K |
Retained Earnings | -14.48M | -26.36M | -39.56M | -56.92M | -72.81M | -101.83M | -131.6M | -153.37M | -206M | -218.85M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 35K | 31K | 65K | 41K | 12K | -9K | -41K | 10K | -52K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MBRX Cash Flow Statement
Moleculin Biotech, Inc. (MBRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -7.32M | -12.2M | -17.2M | -17.77M | -18.95M | -27.64M | -24.1M | -23.86M | -22.73M | -24.28M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -94.53% | -66.62% | -40.93% | -3.33% | -6.64% | -45.84% | 12.8% | 0.99% | 4.72% | -51.45% |
Net Income | -9.8M | -11.88M | -13.21M | -17.36M | -15.89M | -29.02M | -29.77M | -21.76M | -33.56M | -30.33M |
Depreciation & Amortization | 18K | 68K | 199K | 200K | 164K | 130K | 127K | 126K | 90K | 66K |
Stock-Based Compensation | 707K | 1.14M | 1.54M | 1.68M | 2.37M | 2.27M | 1.98M | 1.73M | 1.66M | 1.26M |
Deferred Taxes | -1.39M | 0 | 0 | -2.34M | -6.73M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.6M | -3.15M | -3.59M | 85K | 96K | -1.24M | 1.94M | -4.18M | 8.52M | 3.75M |
Working Capital Changes | 542K | 1.61M | -2.14M | -41K | 1.04M | 224K | 1.62M | 231K | 555K | 980K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 411K | 436K | 907K | -1.02M | 235K | 731K | 403K | -468K | 1.33M | 1.72M |
Cash from Investing | -28K | -417K | -51K | -374K | -19K | -67K | -124K | -13K | 0 | 0 |
Capital Expenditures | -28K | -417K | -52K | -376K | -19K | -67K | -124K | -13K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 2K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 10.06M | 12.04M | 20.85M | 22.55M | 74.72M | -23K | 4.65M | 4.63M | 27.28M | 26.9M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 6.07M | 12.03M | 19.29M | 22.56M | 74.68M | -23K | 4.17M | 4.66M | 27.29M | 26.9M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.76M |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -23K | 0 | 0 | 0 | 0 |
Other Financing | 3.99M | 20K | 1.56M | -12K | 40K | 0 | 485K | -25K | -8K | 1.76M |
Net Change in Cash | 2.71M▲ 0% | -580K▼ 121.4% | 3.6M▲ 720.9% | 4.44M▲ 23.2% | 55.73M▲ 1155.7% | -27.76M▼ 149.8% | -19.59M▲ 29.4% | -19.27M▲ 1.6% | 4.6M▲ 123.9% | 2.6M▲ 0% |
Free Cash Flow | -7.35M▲ 0% | -12.62M▼ 71.7% | -17.25M▼ 36.7% | -18.15M▼ 5.2% | -18.97M▼ 4.5% | -27.71M▼ 46.1% | -24.23M▲ 12.6% | -23.88M▲ 1.4% | -22.73M▲ 4.8% | -24.28M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -94.17% | -71.65% | -36.69% | -5.2% | -4.54% | -46.05% | 12.56% | 1.44% | 4.77% | -11.79% |
FCF per Share | -890.83 | -1096.15 | -953.14 | -691.18 | -264.69 | -363.22 | -306.55 | -173.36 | -1.92 | -0.59 |
FCF Conversion (FCF/Net Income) | 0.75x | 1.03x | 1.30x | 1.02x | 1.19x | 0.95x | 0.81x | 1.10x | 0.68x | 0.80x |
Interest Paid | 0 | 5K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 21K | 19K | 24K | 15K | 0 | 0 | 0 | 0 | 0 |
MBRX Key Ratios
Moleculin Biotech, Inc. (MBRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -61.13% | -75.67% | -88.5% | -103.74% | -32.81% | -44.25% | -76.07% | -135.8% | -319.85% | 3114.17% |
Return on Invested Capital (ROIC) | -66.04% | -136.24% | -212.79% | -360.78% | -306.46% | -258.99% | -352.92% | -757.42% | -434.51% | 225.29% |
Debt / Equity | - | - | 0.02x | 0.02x | 0.00x | 0.01x | 0.02x | 0.08x | 0.02x | 0.01x |
FCF Conversion | 0.75x | 1.03x | 1.30x | 1.02x | 1.19x | 0.95x | 0.81x | 1.10x | 0.68x | 0.80x |
Related:MBRX Dividend History·MBRX Revenue History·MBRX Price History·MBRX P/E History·MBRX Financial Ratios·MBRX Institutional Holders
MBRX SEC Filings & Documents
Moleculin Biotech, Inc. (MBRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
MBRX Frequently Asked Questions
Moleculin Biotech, Inc. (MBRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Moleculin Biotech, Inc. (MBRX) grew revenue by 0.0% over the past year. Growth has been modest.
Moleculin Biotech, Inc. (MBRX) reported a net loss of $30.3M for fiscal year 2025.
Dividend & Returns
Moleculin Biotech, Inc. (MBRX) has a return on equity (ROE) of -319.8%. Negative ROE indicates the company is unprofitable.
Moleculin Biotech, Inc. (MBRX) had negative free cash flow of $24.3M in fiscal year 2025, likely due to heavy capital investments.